Glaukos Corporation (GKOS) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Glaukos Corporation Announces Second Quarter 2017 Financial Results
August 2, 2017 4:10 PM EDTSAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2017. Key highlights include:
Achieved 45% net sales growth to $41.3 million in the second quarter of 2017, compared to $28.6 million in the second quarter of 2016. Increased gross margin to 87% in the second quarter of 2017, compared to 85% in the second quarter of 2016.... More